Aminophylline reduces the risk of death in people with septic shock.

Published Date: 10 Mar 2023

A recent study by Ruifang Zhang and colleagues showed that aminophylline reduced the risk of death and prolonged survival in patients with sepsis. more...

Read Full News

Latest News

Maternal BMI and Birth Length Tied to Dermatitis Risk

A higher maternal prepregnancy BMI and greater birth length are associated with an elevated risk for atopic dermatitis in offspring by 3 years of age, new research shows.

Diabetologists On the Rise as Disease Overwhelms Practices

The launch of the American College of Diabetology has helped dozens of physicians become board-certified, with more on the way.

CMA Funds Program to HELP International Physicians Practice

A new commitment will support a program that familiarizes internationally trained physicians with medical English and the Canadian healthcare system.

Doctors Fired After Unionizing Win Settlement From Employer

Peak Vista Community Health Centers will pay $1.2 million to four physicians and a nurse practitioner after a decision by the National Labor Relations Board.

Medical Bulletin 09/December 2023.

The most important medical news of the day is as follows: early age at first menstrual cycle associated with increased risk of diabetes in middle age.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Latest News

A higher maternal prepregnancy BMI and greater birth length are associated with an elevated risk for atopic dermatitis in offspring by 3 years of age, new research shows.

The launch of the American College of Diabetology has helped dozens of physicians become board-certified, with more on the way.

A new commitment will support a program that familiarizes internationally trained physicians with medical English and the Canadian healthcare system.

Peak Vista Community Health Centers will pay $1.2 million to four physicians and a nurse practitioner after a decision by the National Labor Relations Board.

The most important medical news of the day is as follows: early age at first menstrual cycle associated with increased risk of diabetes in middle age.

News All Time

Check the facts: Posts on social media asserting that biology is not necessary for NEET UG are false.

posts on social media asserting that biology coursework is no longer necessary for those aspiring to become doctors in order to take the National Eligibility-cum-Entrance Test.

Kerala High Court orders Time-Bound Immediate Investigation into Unnecessary Embarrassment of Doctors from Delayed Medical Negligence Probe.

New Delhi: The Kerala High Court on Monday highlighted the possibility that physicians who are innocent could be subjected to needless humiliation should the investigation delay.

Eugene A. Woods joins the board of directors at JnJ.

Johnson and Johnson has announced in New Brunswick that Eugene A. The new CEO of Advocate Health is Woods, MBA, MHA.

Only 30% of doctors' families who passed away from COVID-19 received compensation up until 2023:RTI.

In response to a Right to Information query asking about the total Covid martyrs compensated under the Pradhan Mantri Garib Kalyan Package (PMGKP),.

Medical students from Manipur who have been displaced are able to pursue their education via online or hybrid modes thanks to NMC.

The Undergraduate Medical Education Board (UGMEB) of the National Medical Commission (NMC) has permitted displaced parties, providing a remarkable reprieve.

Incorporate the Ankle Brachial Index examination to rule out peripheral artery disease: A CDSCO Panel Notifies Lupin Regarding Denosumab PK/PD Research.

New Delhi: Under the Central Drug Standard Control, the Subject Expert Committee (SEC) has approved the drug major Lupin.

Delhi High Court: MCI sanctions cannot be used as a yardstick for determining a doctor's shortcomings, flaws, or insufficiency.

New Delhi: The Delhi High Court recently declared that the punishment awarded by the MCI, which is now the National Medical Commission (NMC), could not be an.

As per JAMA, Prone Positioning Has No Effect on the Length of ECMO Weaning in Covid Patients with Severe ARDS.

According to Matthieu Schmidt and colleagues, a randomized clinical trial examined the effects of prone positioning on patients suffering from severe acute respiratory distress.

Rituximab and glucocorticoids in Wegener's Granulomatosis: A PMS Study Report approved by the CDSCO Panel.

New Delhi: The Central Drug Standard Control Organization (CDSCO)'s Subject Expert Committee (SEC) has authorized a post-marketing.

The manufacture and marketing of Azelnidipine and Metoprolol FDC tablets has been approved by the CDSCO Panel for Akum Pharmaceutical.

New Delhi: The Subject Expert Committee (SEC) operating under the Central Drug Standard has given the go-ahead to the pharmaceutical giant Akum Pharmaceuticals.

Health Bulletin / November 30, 2023.

Following a spike in respiratory cases, Uttarakhand and Karnataka are on alert due to a pneumonia outbreak in China. These are the top health stories of the day.

The MP government issues a directive to Yatharth Hospital to assume control of the Ramraja Hospital grounds.

MP: As a result of an order from the Commissionerate of Sagar Sambhag, Madhya, Yatharth Hospital experienced significant trouble yesterday.

Check Your Information: Media reports asserting that biology is not necessary for NEET UG are false.

New Delhi: Posts on social media assert that biology coursework is no longer necessary for applicants to the National Exam to pursue careers in medicine.

The deadline to submit course preferences, willingness to work, and fee for the special straw vacancy round for PG medical seats in Puducherry is today.

The Centralized Admission Committee (CENTAC) in Puducherry has released a notification concerning the special stray vacancy round for three open NEET PG seats.

A radiologist found guilty of violating the PC PNDT Act received a two-year rigorous prison sentence.

A session court in Jabalpur has found a DMRD doctor guilty of a heinous violation of the Pre-Conception and Pre-Natal Diagnostic Techniques (PCPNDT) Act.

Provide Justification for Research on Tocilizumab in Patients with Giant Cell Arteritis: Cipla Hears from the CDSCO Panel.

Examining the procedure that the pharmaceutical company Cipla submitted for the approval of post-marketing active surveillance of tocilizumab in patients in New Delhi.

Recommended News For You

Nuclear missile workers are contracting cancer: They blame the bases

High Rate of Deep Remission for Relapsed/Refractory CLL Using Triple Regimen.

Morning Immunotherapy Does Not Boost Lung Cancer Survival

New methods show how fast breast cancers grow and how surgery delays affect cancer staging

New clinical recommendation for local treatment of oligometastatic lung cancer.

A study outlines the need for policies that enhance cancer patients' autonomy and information.

Radiation therapy for patients with breast cancer

Recommended Articles For You

The Surprising Role of Magnesium in Digestion, Sleep and Mental Health  

Insights into Doxorubicin and Liposomal Doxorubicin in Extra-Abdominal Desmoid-Type Fibromatosis 

A Comprehensive Guide to Carcinoma in Situ: Types, Risks, and Preventive Measures 

Tumor Microenvironment Readiness as a Predictor of Cancer Progression 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study

2.

New methods show how fast breast cancers grow and how surgery delays affect cancer staging

3.

Some low-grade prostate cancers carry higher risks than biopsy suggests

4.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

5.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

1.

Unraveling the Mysteries of Hematocrit: How It Impacts Your Health

2.

Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy

3.

Clinical Pharmacology of Erythroid Maturation Pathway Regulators

4.

Precision Medicine for Bone Marrow Microenvironment Remodeling

5.

Everything You Need to Know About HTLV: A Comprehensive Guide 

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

2.

A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

3.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot